HCA Healthcare reported robust Q2 2024 results with revenues reaching $17.492 billion and net income of $1.461 billion ($5.53 per share), driven by strong patient volumes. Same facility admissions increased 5.8% while emergency room visits rose 5.5% compared to Q2 2023. Revenue per equivalent admission grew 4.4% year-over-year.The company demonstrated solid operational performance with Adjusted EBITDA of $3.550 billion, up from $3.056 billion in Q2 2023. During the quarter, HCA repurchased 4.217 million shares for $1.367 billion and declared a quarterly dividend of $0.66 per share, payable on September 30, 2024.Based on strong performance, HCA raised its 2024 guidance, now projecting revenues of $69.75-71.75 billion, net income of $5.675-5.975 billion, and EPS of $21.60-22.80. Capital expenditures for 2024 are estimated at $5.1-5.3 billion, excluding acquisitions.

HCA Healthcare reported robust Q2 2024 results with revenues reaching $17.492 billion and net income of $1.461 billion ($5.53 per share), driven by strong patient volumes. Same facility admissions increased 5.8% while emergency room visits rose 5.5% compared to Q2 2023. Revenue per equivalent admission grew 4.4% year-over-year.The company demonstrated solid operational performance with Adjusted EBITDA of $3.550 billion, up from $3.056 billion in Q2 2023. During the quarter, HCA repurchased 4.217 million shares for $1.367 billion and declared a quarterly dividend of $0.66 per share, payable on September 30, 2024.Based on strong performance, HCA raised its 2024 guidance, now projecting revenues of $69.75-71.75 billion, net income of $5.675-5.975 billion, and EPS of $21.60-22.80. Capital expenditures for 2024 are estimated at $5.1-5.3 billion, excluding acquisitions.